Overview

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

Status:
NOT_YET_RECRUITING
Trial end date:
2030-11-24
Target enrollment:
Participant gender:
Summary
to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
acalabrutinib
glofitamab
Rituximab
zanubrutinib